Mesalamine ( DrugBank: Mesalamine )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	9
97	潰瘍性大腸炎	99
98	好酸球性消化管疾患	1
164	眼皮膚白皮症	1

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01696942 (ClinicalTrials.gov)	February 2013	25/9/2012	Cimzia Versus Mesalamine for Crohn's Recurrence	Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for ...	Crohn's Disease	Drug: Cimzia;Drug: Mesalamine	Milton S. Hershey Medical Center	UCB Pharma	Terminated	18 Years	N/A	All	10	Phase 4	United States
2	NCT00862121 (ClinicalTrials.gov)	April 2009	13/3/2009	A Study With Pentasa in Patients With Active Crohn's Disease	PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sac ...	Crohn´s Disease	Drug: Pentasa;Drug: Placebo	Ferring Pharmaceuticals	NULL	Terminated	18 Years	N/A	All	20	Phase 3	United States;Belgium;Denmark;France;Germany;Sweden;United Kingdom;Spain
3	NCT00245505 (ClinicalTrials.gov)	February 2009	26/10/2005	The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active Drug: Crohn's Disease	The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s ...	Crohn's Disease	Drug: Mesalazine (Mesalamine)	Ferring Pharmaceuticals	NULL	Terminated	18 Years	70 Years	Both	3	Phase 3	Sweden
4	EUCTR2008-002100-26-BE (EUCTR)	28/01/2009	31/07/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		France;Belgium;Denmark;Germany;United Kingdom;Sweden
5	EUCTR2008-002100-26-FR (EUCTR)	16/01/2009	02/09/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510	Phase 3	France;Belgium;Denmark;Germany;United Kingdom;Sweden
6	EUCTR2008-002100-26-GB (EUCTR)	07/01/2009	19/08/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		Germany;United Kingdom;Denmark;Belgium;France;Sweden
7	EUCTR2008-002100-26-SE (EUCTR)	27/11/2008	08/08/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		Germany;United Kingdom;Denmark;Belgium;France;Sweden
8	EUCTR2008-002100-26-DE (EUCTR)	19/11/2008	06/03/2009	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		France;Belgium;Denmark;Germany;United Kingdom;Sweden
9	EUCTR2008-002100-26-DK (EUCTR)	04/11/2008	18/08/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		Germany;United Kingdom;Belgium;Denmark;France;Sweden

First Previous1Next Last

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 10 of 99 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05753267 (ClinicalTrials.gov)	February 28, 2023	22/2/2023	Fenofibrate in Ulcerative Colitis	Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis	Inflammatory Bowel Diseases	Drug: Mesalamine;Drug: Fenofibrate 160mg	Tanta University	Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University;Hend El-Said Abo Mansour, Faculty of Pha ...	Recruiting	18 Years	75 Years	All	60	Phase 2/Phase 3	Egypt
2	NCT05567068 (ClinicalTrials.gov)	February 1, 2023	1/10/2022	Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis	Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamineby Modulation of ...	Inflammatory Bowel Diseases	Drug: Atorvastatin 80mg;Drug: Mesalamine	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	44	Phase 2	NULL
3	NCT05574387 (ClinicalTrials.gov)	January 20, 2023	6/10/2022	Metformin as Added on Therapy in Patients With Ulcerative Colitis	Metformin, The Biguanide Derivative, as Adjuvant Therapy in Patients With Ulcerative Colitis Treated ...	Inflammatory Bowel Diseases	Drug: Metformin	Tanta University	Principal Investigator Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University;Principa ...	Recruiting	18 Years	75 Years	All	46	Phase 2	Egypt
4	NCT05316220 (ClinicalTrials.gov)	December 31, 2022	31/3/2022	A Study to Assess Adverse Events and Change in Disease Condition of MesalamineCapsules in Children A ...	A Randomized, Double-blind Study to Assess the Safety and Efficacy of MesalamineDelayed-release Caps ...	Ulcerative Colitis (UC)	Drug: Mesalamine;Drug: Placebo	AbbVie	NULL	Not yet recruiting	5 Years	17 Years	All	80	Phase 3	United States;Puerto Rico
5	NCT05553704 (ClinicalTrials.gov)	November 1, 2022	20/9/2022	Metformin in Patients With Ulcerative Colitis Treated With Mesalamine	Clinical Study to Compare the Possible Efficacy of Metformin in Patients With Ulcerative Colitis Tre ...	Inflammatory Bowel Diseases	Drug: Metformin	Tanta University	NULL	Recruiting	18 Years	75 Years	All	52	Phase 2	Egypt
6	NCT05626166 (ClinicalTrials.gov)	November 2022	9/11/2022	the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis	Clinical Study Evaluating the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis Tre ...	Ulcerative Colitis	Drug: Placebo;Drug: Diosmin	Tanta University	NULL	Not yet recruiting	18 Years	N/A	All	60	Phase 3	NULL
7	NCT05558761 (ClinicalTrials.gov)	October 10, 2022	25/9/2022	Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis	Clinical Study to Evaluate the Possible Efficacy of Pentoxifylline in Patients With Ulcerative Colit ...	Inflammatory Bowel Diseases	Drug: Pentoxifylline 400 MG	Tanta University	NULL	Recruiting	18 Years	75 Years	All	50	Phase 2	Egypt
8	NCT05119140 (ClinicalTrials.gov)	June 10, 2022	20/10/2021	HCQ for Non Europeans With Mild to Severe UC	Administration of Hydroxychloroquine (Plaquenil) to Individuals of Non-European Ancestry for the Tre ...	Ulcerative Colitis (Disorder)	Drug: Hydroxychloroquine;Drug: Mesalamine	Icahn School of Medicine at Mount Sinai	Crohn's and Colitis Foundation	Recruiting	18 Years	N/A	All	20	Phase 1/Phase 2	United States
9	ChiCTR2000037261	2020-10-01	2020-08-27	Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exo ...	Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exo ...	Ulcerative Colitis	experimental group:stasis removing and immunoregulation therapy;control group:mesalamine;	Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Trad ...	NULL	Recruiting	18	65	Both	experimental group:30;control group:30;		China
10	NCT03923478 (ClinicalTrials.gov)	June 24, 2019	15/4/2019	ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, ...	Ulcerative Colitis Chronic Mild;Ulcerative Colitis Chronic Moderate	Drug: ABI-M201;Drug: Placebo	Assembly Biosciences	NULL	Terminated	18 Years	70 Years	All	15	Phase 1	United States;Canada

First Previous1 2 3 4 5…10Next Last

先頭へ

98. 好酸球性消化管疾患

臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05488405 (ClinicalTrials.gov)	February 9, 2022	3/8/2022	Mesalazine Oral Suspension in Active Eosinophilic Esophagitis	Open-label, Monocentric Phase IIa Pilot Study Evaluating the Efficacy and Tolerability of a 4-week T ...	Eosinophilic Esophagitis	Drug: Mesalamine Oral Product	Dr. Falk Pharma GmbH	NULL	Recruiting	18 Years	75 Years	All	10	Phase 2	Switzerland

First Previous1Next Last

164. 眼皮膚白皮症

臨床試験数 : 15 / 薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00514982 (ClinicalTrials.gov)	August 7, 2007	9/8/2007	Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome	An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disea ...	Hermanski-Pudlak Syndrome;Colitis;Cytokines;Lymphocytes;Drug Evaluation	Drug: Mesalamine;Drug: Infliximab;Drug: Corticosteroids;Drug: 6-Mercaptopurine;Drug: Tacrolimus;Drug ...	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	United States

First Previous1Next Last

先頭へ